A 172

Human glioblastoma cell lines were obtained as follows: U-251 MG, T98G, SF126, A-172, AM38, and YH-13, JCRB Cell Bank (Osaka, Japan); DBTRG-05 MG, LN-229, LN-18 and M059K, ATCC (Manassas, VA). These cell lines were maintained in RPMI1640 supplemented with 10% fetal bovine serum (FBS) and cultured at 37°C in a humidified atmosphere containing 5% CO₂.

A172, LN229 and T98G cell lines were purchased from the American Type Culture Collection (ATCC) (Manassas, VA) and KALS-1 were from JCRB cell bank (Osaka, Japan) (A172: ATCC Cat#CRL-1620, RRID:CVCL_0131, KALS-1: JCRB Cat#IFO50434, RRID:CVCL_1323, LN229: ATCC Cat#CRL-2611, RRID:CVCL_0393, T98G: Cat#CRL-1690, RRID:CVCL_0556). Cells were supplemented with Dulbecco’s modified Eagle’s medium (DMEM), 10% heat-inactivated foetal bovine serum and 1% penicillin-streptomycin at 37 °C in a humidified incubator with an atmosphere of 5% CO₂. As a patient-derived brain tumour-initiating cell, HCM-BROD-0417-C71 was purchased from ATCC (Cat#PDM-379) and cultured with conditioned media supplemented with NeuroCult™ NS-A Proliferation Kit (Cat#05751; STEMCELL Technologies, Vancouver, Canada), 20 ng/mL EGF (Cat#236-EG-200; R&D Systems, Minneapolis, MN), 20 ng/mL bFGF (Cat#100-18B; Peprotech, Cranbury, NJ) and 2 µg/mL Heparin (Cat#07980; STEMCELL Technologies). All cells were used in experiments up to the 15th passage. Cells had been tested for mycoplasma (Venor Gem Classic; Minerva Biolabs, Berlin, Germany), the last test being in 07/02/2019.